Medications designed to help people lose weight, such as Ozempic and Wegovy, have gained widespread attention in recent years. These drugs belong to a class called GLP-1 receptor agonists, which help control hunger and support weight loss.
While they can be very effective, a new study suggests that their benefits may decrease if they are not taken consistently.
The study was carried out by researchers at the University of Pennsylvania’s Perelman School of Medicine and published in the Journal of Clinical Investigation Insight. It looked at how patterns of use, especially stopping and restarting the medication, might affect its ability to help people lose weight.
Many people who start GLP-1 medications do not stay on them continuously. Real-world data show that more than half of patients stop treatment within two years. Some later return to using the medication, creating cycles of use and non-use. This pattern led researchers to question whether the drug works the same way each time it is restarted.
To explore this question, the research team conducted an experiment using overweight mice. The mice were divided into two groups. One group received the drug continuously over four months.
The other group followed a pattern of taking the drug for two weeks, stopping for two weeks, and repeating this cycle several times before returning to continuous use.
At first, both groups responded well to the treatment. They lost a similar amount of weight during the early stages. However, the group that stopped the drug regularly regained weight during each break. When they started the drug again, they did not lose as much weight as they had during the first cycle.
Even after switching to continuous treatment later in the study, the intermittent group did not catch up. By the end of the experiment, they were still about 20 percent heavier than the group that had taken the drug without interruption.
The researchers believe this effect is linked to changes in the body’s composition. When weight is lost, both fat and muscle are reduced. However, when weight is regained after stopping the drug, most of the gain is fat. This changes the balance between muscle and fat in the body.
Over time, the body may resist further weight loss to protect muscle mass. The researchers describe this as a protective response. Once the body reaches a certain level of muscle loss, it may become harder to lose additional weight, even when the medication is restarted.
These findings suggest that the body adapts to changes in treatment, and that repeated cycles of stopping and restarting may make weight loss more difficult. The study also highlights the importance of maintaining muscle through exercise and nutrition while using these medications.
When analyzing the study, it is important to recognize both its strengths and its limits. The controlled design allowed researchers to clearly observe patterns, but the study was conducted in mice rather than humans. Human behavior, diet, and metabolism are more complex, so further research is needed to confirm whether the same effects occur in people.
Despite these limitations, the study provides a useful message. It suggests that consistency may be critical for achieving the full benefits of GLP-1 medications. It also raises awareness that stopping treatment may have long-term effects on how the body responds.
In conclusion, this research adds an important piece to the understanding of weight-loss medications. It shows that these drugs are not just about starting treatment, but also about maintaining it over time. Future studies will help determine how these findings apply to patients and how treatment plans can be improved for better long-term success.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies that Mediterranean diet can reduce belly fat much better, and Keto diet could help control body weight and blood sugar in diabetes.
Source: University of Pennsylvania.
